MENU
+Compare
CYCN
Stock ticker: NASDAQ
AS OF
May 8 closing price
Price
$3.16
Change
-$0.27 (-7.87%)
Capitalization
10.45M

CYCN Cyclerion Therapeutics Forecast, Technical & Fundamental Analysis

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases... Show more

CYCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for CYCN with price predictions
May 08, 2025

CYCN's RSI Oscillator leaves overbought zone

The 10-day RSI Indicator for CYCN moved out of overbought territory on April 29, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 50-day moving average for CYCN moved below the 200-day moving average on April 15, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYCN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CYCN broke above its upper Bollinger Band on April 25, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 75 cases where CYCN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on April 14, 2025. You may want to consider a long position or call options on CYCN as a result. In of 107 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

CYCN moved above its 50-day moving average on April 22, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CYCN crossed bullishly above the 50-day moving average on April 23, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CYCN advanced for three days, in of 220 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 122 cases where CYCN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.036) is normal, around the industry mean (14.243). P/E Ratio (0.000) is within average values for comparable stocks, (62.770). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.866). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (3.789) is also within normal values, averaging (253.449).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CYCN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYCN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
CYCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

CYCN is expected to report earnings to rise 75.00% to -28 cents per share on August 08

Cyclerion Therapeutics CYCN Stock Earnings Reports
Q2'23
Est.
$-0.28
Q1'23
Beat
by $0.14
Q4'22
Beat
by $0.12
Q3'22
Beat
by $5.96
Q2'22
Missed
by $0.01
The last earnings report on May 11 showed earnings per share of -15 cents, beating the estimate of -30 cents. With 4.40K shares outstanding, the current market capitalization sits at 10.45M.
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical products for serious and orphan diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
245 First Street
Phone
+1 857 327-8778
Employees
1
Web
https://www.cyclerion.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NCGFX60.42N/A
N/A
New Covenant Growth
GLCGX28.03N/A
N/A
Goldman Sachs Large Cap Gr Insghts A
JSIGX19.78N/A
N/A
Jacob Small Cap Growth Institutional
TNVIX15.77N/A
N/A
1290 GAMCO Small/Mid Cap Value I
PWJDX32.08N/A
N/A
PGIM Jennison International Opps R4

CYCN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CYCN has been loosely correlated with BLUE. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CYCN jumps, then BLUE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYCN
1D Price
Change %
CYCN100%
-7.94%
BLUE - CYCN
37%
Loosely correlated
+0.54%
HRTX - CYCN
33%
Poorly correlated
-3.98%
GDTC - CYCN
31%
Poorly correlated
+2.91%
FATE - CYCN
29%
Poorly correlated
+3.00%
IBIO - CYCN
25%
Poorly correlated
-2.26%
More